News

Essential Properties Realty Trust (EPRT) reported first‑quarter 2026 results that exceeded expectations across key metrics. Net income per share rose 13 % to $0.28, while Adjusted Funds From Operations (AFFO) per share increased 11 % to $0.50, matching the $0.5 per share FFO that beat the Zacks Consensus Estimate of $0.49 per share by 2.04 %. Reven...

Full article

The cost reduction was partly offset by an algae bloom in Southern Norway, which negatively impacted costs by around EUR 10 million or EUR/kg 0.13 for Norwegian volumes. The company's operational EBIT per kg through the value chain varied across regions, with Norway achieving EUR 2.40 and Scotland EUR 1.50. In Consumer Products, operational EBIT wa...

Full article

Mowi ASA's first quarter 2026 harvest volumes reached a record high, increasing by 26% year-over-year to 136 thousand tonnes. This exceeded the company's guided total harvest volume of 128k GWT for Q1 2026. The operational EBIT for the Group was approximately EUR 221 million in Q1 2026, with blended farming costs decreasing to EUR/kg 5.46 from EUR/...

Full article

Financially, Roche’s core medicines—Hemlibra, Phesgo, and Gazyva—continue to support revenue streams, with the company’s shares up 3 % year‑to‑date against an industry decline of 5.5 %. The combined clinical advances and sales momentum are expected to underpin investor expectations for a strong future outlook, while the fenebrutinib safety data wil...

Full article

Strategically, the fenebrutinib data reinforce Roche’s plan to broaden its neuroscience portfolio as Ocrevus approaches patent expiry in the coming decade. A first‑in‑class BTK inhibitor that could occupy the high‑efficacy oral niche in both relapsing MS and primary progressive MS would be a key growth driver for the pharmaceutical segment. Ens­pry...

Full article

Roche also highlighted progress for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE). The ALLEGORY Phase III study, now under FDA review, showed 76.7 % of patients achieved a clinical response versus 53.5 % on placebo, a result that could lead to approval by December 2026. Gazyva/Gazyvaro generated CHF 986 million in 2025 sales, a 14 % year‑ov...

Full article

Ens­pryng’s Phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD) reached its primary endpoint, reducing the risk of a new relapse by 68 % versus placebo. At 48 weeks, 87 % of Ens­pryng recipients remained relapse‑free compared with 67 % on placebo. MRI data demonstrated a 79 % reduction in the annual...

Full article

Roche’s Phase III data on fenebrutinib and Enspryng, the company’s two front‑line neurological assets, were disclosed on Tuesday. In the FENhance 1 and 2 studies, fenebrutinib reduced the annualized relapse rate in relapsing multiple sclerosis (RMS) by 51.1 % and 58.5 % versus teriflunomide over 96 weeks, a benefit that translates to an average of...

Full article

The company, CMB.TECH NV, has published its annual report for the year ended December 31, 2025. The report is available on the company’s website and has also been filed with the U.S. Securities and Exchange Commission as Form 20‑F. Shareholders are invited to participate in the Annual General Meeting and Special General Meeting on May 21, 2026, whe...

Full article

Analyst activity has been mixed. Keefe Bruyette maintains an Outperform rating but lowered its price target to $2,300 from $2,375. Deutsche Bank downgraded FCNCA to Hold from Buy with a $2,154 target, and JPMorgan cut its target to $2,200 from $2,450, downgrading to Neutral from Overweight. The downgrades stem from concerns about the company’s SVB...

Full article